RE:RE:RE:RE:RE:RE:RE:RE:So far so good Thanks for those. Do you remember last year if the VM was talked about in the pre-released abstracts? As you know, there was not much reaction to the abstracts being released but there was a huge reaction once the conference actually took place. Did new info come out at the conference that was not included in the abstracts? Might that ahppen again if it happened in 2020? Or is it just a case of the market being very inefficient in not understading innitially what was in the abstracts? On the other hand, it might simply have been that the bubble market conditions, which were stronger at that time than they are now (although still present to some degree), are the principal reason for the outsized reaction last year.
jfm1330 wrote: Here are links to the two abstracts. There is nothing fundamentally new in these abstracts. They prove overexpression of sortilin receptor, the affinity of their peptide to sortilin (it means their peptide binds with sortilin), and they show in vivo effect on animal models in cancer types they did not tested before. Nothing to do a webcast about. The basic principles for non scientific investors can be explained very quickly and are easy to understand. It works on xenograft of selected cancer tumor in mice. We already knew that. The big question is will it work on a real heterogenous tumor (not a selected one) in the human body, with human enzymes to degrade the PDC, etc.. If I would be in the places of Levesque and Marsolais I would not sound overly optimistic in April, only to look like a fool, or a crook a few months later id it does not work on human. Thera is an honest company, not Cytodyn.
https://www.abstractsonline.com/pp8/#!/9325/presentation/2039
https://www.abstractsonline.com/pp8/#!/9325/presentation/2111